| Macitentan |
| N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide |
| (CAS 441798-33-0) |
 |
| Description： |
Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH).[1] The other two ERAs marketed as of 2014 are bosentan and ambrisentan.[1] Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB.[1] However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.[2] The drug received approval from the U.S. Food and Drug Administration (FDA) on October 13, 2013.[3] |
| Product No. |
KT00036 |
| Product Name |
Macitentan |
| Synonyms |
|
| Formal Name |
N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide |
| CAS Number |
441798-33-0 |
| Molecular Formula |
C19H20Br2N6O4S |
| Formula Weight |
588.27 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
1 year |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
Fingolimod (FTY720) HCl
Cyclopamine
Vismodegib (GDC-0449)
Bosentan
Bosentan Hydrate
Sitaxentan sodium |
|
